ADMA Biologics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ADMA Biologics, Inc. on June 28, 2018. The report addresses Item 5.02 regarding the appointment of certain officers and compensatory arrangements. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation adjustments.
Material Changes
The Board of Directors approved retroactive annual base salary increases for three Named Executive Officers (NEOs), effective January 1, 2018. This action follows a prior agreement to revisit salaries after the 2018 Annual Meeting of Stockholders. The increases were designed to align compensation with the 50th percentile of a peer group selected following the acquisition of the Biotest Therapy Business Unit. Prior to this adjustment, the last salary increases for these officers occurred in January 2016.
| Name | Position | Annual Base Salary (Retroactive to Jan 1, 2018) |
|---|---|---|
| Adam S. Grossman | President, CEO, and Director | $536,000 |
| Dr. James Mond | EVP, CSO, and CMO | $401,800 |
| Brian Lenz | EVP and CFO | $366,800 |
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of risks and contingencies. Management commentary indicates that salary increases were withheld during the integration and remediation activities following the Biotest acquisition and were only granted once progress was made.
Key Facts for Investor Verification
- Verify the specific peer group used by the independent compensation consultant to determine the 50th percentile benchmark.
- Confirm the total financial impact of the retroactive salary adjustments on the Company's 2018 operating expenses.
- Review the status of the integration and remediation activities related to the Biotest Therapy Business Unit acquisition.
- Check subsequent filings for any further changes to executive compensation or the peer group composition.